Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Merus N.V. (MRUS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/31/2019 |
6-K
| Quarterly results |
| 12/16/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 12/06/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/18/2019 |
6-K
| Quarterly results |
| 11/12/2019 |
6-K
| Quarterly results |
| 11/06/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/04/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/19/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"Unaudited financial statements for Merus N.V. as of and for the three and six months ended June 30, 2019",
"Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update UTRECHT, The Netherlands, August 19, 2019 — Merus N.V. , a clinical-stage immuno-oncology company developing Biclonics ® , innovative full-length human bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2019 and provided a business update. “We have made good progress with our clinical programs in the second quarter and have achieved further clarity with our clinical trial plans,” said Ton Logtenberg, Ph.D., President, Chief Executive Officer and Principal Financial Officer of Merus. “Patient enrollment for our MCLA-158 and MCLA-145 Phase 1 trials is on track. Importantly, we amended the MCLA-117 T-cell engager trial to allow us to explore higher ..." |
|
| 07/31/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 06/14/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/30/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"FORM 6-K",
"Unaudited financial statements for Merus N.V. as of and for the three months ended March 31, 2019",
"Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update UTRECHT, The Netherlands, May 30, 2019 — Merus N.V. , a clinical-stage immuno-oncology company developing Biclonics ® , innovative full-length human bispecific antibody therapeutics, today announced financial results for the first quarter ended March 31, 2019 and provided a business update. “We had continued momentum in the first quarter following an active 2018,” said Ton Logtenberg, Ph.D., President, Chief Executive Officer and Principal Financial Officer of Merus. “This past month we announced the first patient treated in our fourth clinical program, MCLA-145, and presented promising pre-clinical data for the program at AACR. Merus is rapidly maturing; we are now a team of over 100 employees global..." |
|
| 05/23/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"Convening Notice for Annual General Meeting of Shareholders of Merus N.V., Agenda, and Explanatory Notes to the Agenda",
"Proposed Articles of Association",
"Works Council Response to Request",
"Proxy Card for Registered Holders of Merus N.V",
"Merus Announces 2019 Annual General Meeting of Shareholders UTRECHT, The Netherlands, May 23, 2019 — Merus N.V. , a clinical-stage immuno-oncology company developing Biclonics ® , innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Meeting of Shareholders will be held on June 12, 2019 at 1:00 pm at the offices of NautaDutilh N.V. . All relevant documents and information for the meeting, including the notice and agenda, are available in the ‘Investor Relations' section of Merus' website under “Financial Information”. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics ® . Biclonics ® , which are based on the full-lengt..." |
|
| 04/03/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/02/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 12/27/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 12/27/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"Revised consolidated financial statements for Merus N.V. as at December 31, 2017 and 2016 and for the Years Ended December 31, 2017, 2016, and 2015",
"Revised consolidated financial statements for Merus N.V. as at December 31, 2017 and 2016 and for the Years Ended December 31, 2017, 2016, and 2015",
"Consent of KPMG Accountants N.V" |
|
| 08/10/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 07/27/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 07/26/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 07/05/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"Convening Notice for Annual General Meeting of Shareholders of Merus N.V., Agenda, and Explanatory Notes to the Agenda",
"Dutch Statutory Board Report and Financial Statements of Merus N.V. for the Fiscal Year Ended December 31, 2017",
"Non-Executive Director Compensation Program",
"Changes to Non-Executive Director Compensation Program",
"Proxy Card for Registered Holders of Merus N.V",
"Merus Announces Annual Meeting of Shareholders UTRECHT, The Netherlands, July 5, 2018 — Merus N.V. , a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics , today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20, 2018 at 8:00 a.m. CEST, at the offices of NautaDutilh N.V. . All relevant documents and information for the meeting, including the notice and agenda, are available in the ‘Investor Relations' section of Merus' website under “Financial Information”. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics ® . Biclonics ® , which are based on the full-length IgG format, are manufactured us..." |
|
| 07/02/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 04/27/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/16/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 02/15/2018 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"Securities Purchase Agreement, by and among Merus N.V. and the Investors identified on Exhibit A attached thereto",
"Securities Purchase Agreement, by and among Merus N.V. and the Investors identified on Exhibit A attached thereto",
"Registration Rights Agreement, by and among Merus N.V. and the Investors identified on Exhibit A attached thereto",
"About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics ® . Biclonics ® , which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus' second most advanced bispec..." |
|
| 12/01/2017 |
6-K
| Quarterly results|
Docs:
|
"FORM 6-K",
"Unaudited financial statements for Merus N.V. for the three and nine month periods ended September 30, 2017 and 2016",
"MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS UTRECHT, The Netherlands, November 30, 2017 — Merus N.V. , a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics , today announced financial results for the third quarter ended September 30, 2017 and provided a clinical update. “Merus continues to make meaningful advances with both our proprietary pipeline, led by MCLA-128, and our various collaboration programs,” said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. “We look forward to several milestones over the balance of the year, including our plan to initiate a Phase 2 clinical trial of MCLA-128 in combination with other therapies in HER2 positive and ER+/HER2 low metastatic breast cancer and plan to file a C..." |
|
| 09/22/2017 |
6-K
| Quarterly results |
| 07/11/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 06/06/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 06/01/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 05/09/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 04/28/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 01/25/2017 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 12/21/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] |
| 11/07/2016 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]|
Docs:
|
"6-K",
"Unaudited financial statements for Merus N.V. for the three month period ended September 30, 2016",
"Merus Announces Third Quarter 2016 Financial Results and Corporate Developments Utrecht, The Netherlands, November 7, 2016 — Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the third quarter ended September 30, 2016 and provided a review of recent accomplishments and clinical development plans. “We continued to execute on our clinical strategy during the third quarter, and we are well financed to achieve several key milestones in the coming quarters,” said Ton Logtenberg, PhD, Chief Executive Officer of Merus. “We also further solidified our executive team and expanded our U.S. presence with the appointments of Dr. L. Andres Sirulnik as Chief Medical Officer and John Crowley as Chief Financia..." |
|
|
|
|